Zimbabwe has turned down a substantial American health deal worth 367 million US dollars (£272m) spanning five years due to Washington's request for sensitive biological samples.
The decision came to light following a government memo dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesperson later explained that the United States was demanding access to biological samples for research and commercial purposes but was unwilling to guarantee the benefits from any future vaccines.
"We are forced to start the difficult and regrettable process of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for more talks to secure a agreement suitable to all parties so the nation's critical HIV treatment initiative can be sustained.
Broader Implications
This development comes after a comparable situation in Kenya, where a court blocked a related health funding agreement after legal challenges were filed about the safety of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump argued its expenditure was "wasteful" and his administration was seeking government-to-government deals to enhance openness and responsibility.
Based on statements, Sixteen nations in Africa have to date agreed to these new agreements, representing more than $18.3bn of fresh investment.
Details of the Rejected Deal
The money for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation would have delivered extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy through US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Our nation was requested to share its genetic material and health information over an extended period, with no corresponding promise of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that shared data," Mangwana explained.
"In essence, our country would supply the raw materials for scientific discovery without any certainty that the resulting innovations would be available to our people if a future pandemic arise."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining frameworks already set up through the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to manage potential global health emergencies.
"This mechanism is designed to ensure that when a country contributes its information, the benefits – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to ongoing discussions with our US partners on how future collaboration might be designed in a way that respects the sovereignty and interests of each country."
Health Experts Reaction
Medical experts expressed it acknowledged the official position, but recommended that talks need to persist given that a large portion of the nation's Aids initiatives were funded by external financing.
"If specific concerns exist, including those involving information security or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," it said.
The halted deal underscores the ongoing tensions between receiving vital international aid and protecting a country's data in an ever more data-driven world.